Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Completes Establishment of Four Wholly Owned Subsidiaries
- Lexaria’s technology changes the manner in which edible cannabinoids enter the body
- The company out-licenses its DehydraTECH drug delivery platform
- Lexaria recently announced the creation of four wholly owned subsidiaries
A research-driven company, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is the only company globally that has been awarded a patent for the improved delivery of all cannabinoids. It has developed and out-licenses its DehydraTECH technology – a drug delivery platform. This technology is a complementary layer that works with other research and development being conducted on cannabinoids and, as such, is an enabling technology, not a competing one. Lexaria Bioscience is headquartered in Kelowna, British Columbia, and the company recently uplisted to the OTCQX Best Market.
Lexaria’s process changes the way in which edible cannabinoids enter the body. Its DehydraTECH drug delivery platform is patented for cannabidiol and all other non-psychoactive cannabinoids, as well as for THC (Tetrahydrocannabinol) and psychoactive cannabinoids (http://nnw.fm/p7oPt). The process lessens the time of onset, with cannabinoid effects being experienced within 15 to 20 minutes. Furthermore, the process was proven via human clinical testing to promote increased bio-absorption and, in masking taste, eliminates the requirement for sugar-filled edibles.
The DehydraTECH drug delivery platform facilitates the transportation of bioactive substances by way of oral ingestion. It accomplishes this without the need for inhalational dosing. It is more effective than traditional ingestion and circumvents smoking dangers. While not yet active with the tobacco industry, Lexaria is assessing the potential use of its technology for nicotine delivery. DehydraTECH has been shown to deliver nicotine to the brain quicker than traditional delivery systems. This technology may potentially apply to the treatment of nervous system diseases, including Alzheimer’s.
Lexaria has cannabidiol products developed for demonstration, testing and sales. These products include protein energy bars, exotic teas, cannabidiol tablets and TurboCBD. The company’s exotic teas feature its ViPova brand premium teas, which are anti-oxidant and come in several flavors. Lexaria said that it will use wholly owned Poviva Tea Corp. to advance the existing ViPova tea and coffee consumer brands. TurboCBD are high absorption, full spectrum hemp oil capsules specially formulated with American Ginseng and Gingko Biloba. Lexaria is leading the way with unique product development to serve increasing consumer demand for first-rate cannabidiol products.
Recently, Lexaria announced its completion of the formation of four wholly owned subsidiary companies (http://nnw.fm/8QSxQ). Each of these subsidiaries are vested with the company’s patented DehydraTECH drug delivery platform. The four subsidiaries are Lexaria CanPharm Corp., Lexaria Nicotine Corp., Lexaria Hemp Corp. and Lexaria Pharmaceutical Corp.
Lexaria CanPharm’s emphasis is on providing DehydraTECH technology and other improvements to the worldwide cannabis industry. Lexaria Nicotine administers the company’s nicotine-related patent portfolio. It has an international license to provide DehydraTECH technology to the worldwide nicotine and tobacco industries.
Lexaria Hemp is globally licensed to provide DehydraTECH to the fast developing hemp-based foods and supplements industries. Lexaria Pharmaceutical is in the R&D and product development phase. It will manage the most extensive set of IP of all of the Lexaria family of companies. It can license DehydraTECH to varied pharmaceutical sectors, such as pain relief, vitamins, PDE5 inhibitors, hormone treatments and central nervous system conditions, among others.
With its focus on its DehydraTECH drug delivery platform and innovative product development, Lexaria Bioscience continues to be disruptive in the cannabinoid space. The company’s is dedicated to moving forward with the development and commercialization of first rate technologies and products that address consumers’ demands for cannabinoid innovation. Lexaria’s technology for improved delivery of bioactive compounds bodes well for the future growth of the company.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria’s technology changes the manner in which edible cannabinoids enter the body
- The company out-licenses its DehydraTECH drug delivery platform
- Lexaria recently announced the creation of four wholly owned subsidiaries
A research-driven company, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is the only company globally that has been awarded a patent for the improved delivery of all cannabinoids. It has developed and out-licenses its DehydraTECH technology – a drug delivery platform. This technology is a complementary layer that works with other research and development being conducted on cannabinoids and, as such, is an enabling technology, not a competing one. Lexaria Bioscience is headquartered in Kelowna, British Columbia, and the company recently uplisted to the OTCQX Best Market.
Lexaria’s process changes the way in which edible cannabinoids enter the body. Its DehydraTECH drug delivery platform is patented for cannabidiol and all other non-psychoactive cannabinoids, as well as for THC (Tetrahydrocannabinol) and psychoactive cannabinoids (http://nnw.fm/p7oPt). The process lessens the time of onset, with cannabinoid effects being experienced within 15 to 20 minutes. Furthermore, the process was proven via human clinical testing to promote increased bio-absorption and, in masking taste, eliminates the requirement for sugar-filled edibles.
The DehydraTECH drug delivery platform facilitates the transportation of bioactive substances by way of oral ingestion. It accomplishes this without the need for inhalational dosing. It is more effective than traditional ingestion and circumvents smoking dangers. While not yet active with the tobacco industry, Lexaria is assessing the potential use of its technology for nicotine delivery. DehydraTECH has been shown to deliver nicotine to the brain quicker than traditional delivery systems. This technology may potentially apply to the treatment of nervous system diseases, including Alzheimer’s.
Lexaria has cannabidiol products developed for demonstration, testing and sales. These products include protein energy bars, exotic teas, cannabidiol tablets and TurboCBD. The company’s exotic teas feature its ViPova brand premium teas, which are anti-oxidant and come in several flavors. Lexaria said that it will use wholly owned Poviva Tea Corp. to advance the existing ViPova tea and coffee consumer brands. TurboCBD are high absorption, full spectrum hemp oil capsules specially formulated with American Ginseng and Gingko Biloba. Lexaria is leading the way with unique product development to serve increasing consumer demand for first-rate cannabidiol products.
Recently, Lexaria announced its completion of the formation of four wholly owned subsidiary companies (http://nnw.fm/8QSxQ). Each of these subsidiaries are vested with the company’s patented DehydraTECH drug delivery platform. The four subsidiaries are Lexaria CanPharm Corp., Lexaria Nicotine Corp., Lexaria Hemp Corp. and Lexaria Pharmaceutical Corp.
Lexaria CanPharm’s emphasis is on providing DehydraTECH technology and other improvements to the worldwide cannabis industry. Lexaria Nicotine administers the company’s nicotine-related patent portfolio. It has an international license to provide DehydraTECH technology to the worldwide nicotine and tobacco industries.
Lexaria Hemp is globally licensed to provide DehydraTECH to the fast developing hemp-based foods and supplements industries. Lexaria Pharmaceutical is in the R&D and product development phase. It will manage the most extensive set of IP of all of the Lexaria family of companies. It can license DehydraTECH to varied pharmaceutical sectors, such as pain relief, vitamins, PDE5 inhibitors, hormone treatments and central nervous system conditions, among others.
With its focus on its DehydraTECH drug delivery platform and innovative product development, Lexaria Bioscience continues to be disruptive in the cannabinoid space. The company’s is dedicated to moving forward with the development and commercialization of first rate technologies and products that address consumers’ demands for cannabinoid innovation. Lexaria’s technology for improved delivery of bioactive compounds bodes well for the future growth of the company.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
